Skip to main content
ENDO 2026 Main banner

Neuroendocrinology and Pituitary

SUN-027 - An Exploratory Assessment of the Globe-Reg Registry for Studying the Safety of Long-Acting Growth Hormone in Cancer Survivors (the SAFE-Survivors Study)

Sunday, June 14, 2026
9:00 AM - 4:00 PM CT
Location: ENDOExpo; Poster Floor
Disclosure(s):
Sebastian J.C.M.M Neggers, MD, PhD: recordati: Advisory Board (), Grant Recipient (), Honorarium Recipient ()
Kevin C.J Yuen, MD, FRCP (UK), FACE: Ascendis Pharma: Advisory Board (), Contracted Research (Principal Investigators must provide information, even if received by the institution) (); Camurus: Advisory Board (); Chiesi: Advisory Board (); Crinetics: Advisory Board (); Neurocrine: Advisory Board (), Speakers' Bureau (); Novo Nordisk: Advisory Board (), Contracted Research (Principal Investigators must provide information, even if received by the institution) (), Speakers' Bureau (); recordati: Advisory Board (), Speakers' Bureau (); Sparrow Therapeutics: Contracted Research (Principal Investigators must provide information, even if received by the institution) ()
Introduction
Growth hormone (GH) treatment is approved for survivors of cancer who have GH deficiency. In addition to the well-established use of daily GH, long-acting GH (LAGH) has also been recently approved for the treatment of GHD. The safety of daily GH has been previously studied in cancer survivors with reassuring results. However, given its different mechanistic action, the safety of LAGH in this group needs further study.

Methods
The Global Registry for Novel Therapies in Rare Bone and Endocrine Conditions (https://globe-reg.net/) was initiated in 2022 as a resource for collecting real world data on safety and effectiveness of GH therapy in people of all ages. In late 2025, a non-interventional, retrospective and prospective study, SAFE-Survivors was launched with the aim of using GloBE-Reg to study cases of all ages who receive daily GH or LAGH following a cancer diagnosis; longitudinal data shall be analysed at 12, 24, 60, and 120 months after initiation of GH. The study intends to recruit new cases for a period of 10 years and the current report summarises the preliminary analysis of the first data tranche.

Results
Since its launch in late 2022, 44 centres from 24 countries in 5 continents have enrolled 5,075 cases with a median current age of 12.2 (10th, 90th centile: 6.3, 18.1) in GloBE-Reg. Of these, 2,928 (58%) had growth hormone deficiency (GHD). Among the GHD cohort, 92 (3%) cases from 16 centres received GH following a cancer diagnosis. Of these, 10 (11%) were receiving LAGH, 2 had stopped GH and the remainder were on daily GH. In the first data tranche at the launch of the study, data was available for 74 (80%) cases from 11 centres. The median age at start of therapy and the current age of these cases was 11 yrs (6.4, 14.8) and 14.5 yrs (9.8, 19.2), respectively. This cohort of 74 cases consisted of 64 reports of intracranial tumours including craniopharyngiomas (n,23) and pituitary tumours (n,8). Therapy data was available in 64 cases and the broad groups were surgery only (10), radiation only (3), chemotherapy only (3) and combined (48). The median duration of follow-up data that would be available in this group of cases after GH initiation was 28 months (4.5, 96) with data at 12, 24, 60 and 120 months in 23, 19, 9 and 3 cases respectively. In the data that was available, there were no documented reports of recurrences or secondary cancers.

Conclusion
This initial analysis of the SAFE-Survivors study using the GloBE-Reg platform serves as an important first step in assessing the long-term safety of LAGH in comparison to daily GH treatment in cancer survivors with GHD. No new cancers or recurrences were found in this cohort. However, this is based on a small sample and short follow up time and requires further data clarification. Increased patient recruitment and data collection of the GloBE-Reg over time will be crucial to fully understand the safety of these GH treatments and inform clinical practice.

*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*